BAVARIAN NORNAM.DK 10 overview

COPENHAGEN, Denmark, May 8, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a new share buy-back program, under which the Company intends to buy back up to 162,288 of its own shares. The purpose of the share buy-back program is to meet the Company’s obligations arising from the share-based incentive programs for the Board of Directors and Executive Management, in accordance with the Company’s remuneration policy. The share buy-back program is initiated pursuant to...

COPENHAGEN, Denmark , May 8, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2024. Revenue for the first three months was DKK 831 million, and the operating profit (EBITDA) was DKK 22 million. Revenue from travel health increased by 20% to DKK 447 million and revenue from public preparedness was DKK 344 million, 59% down from first quarter 2023, which is fully in line with expectations after a peak year in...

COPENHAGEN, Denmark, May 7, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. The transactions concern grants of restricted stock units as part of the remuneration of the Board of Directors as adopted at the ordinary general meeting on April 16, 2024. Restricted stock units equivalent to the value...

COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract valued at EUR 65 million to supply its MVA-BN ® smallpox vaccine to the strategic reserve within the European Union (EU) in 2025. This third, and larger order follows two previous orders, received in 2023 and delivered in 2024, for smallpox vaccines to rescEU stockpiles across Europe and will help to expand the EU’s capability to respond to future biological threats and emergencies...

COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA) for the licensure of its CHIKV VLP vaccine candidate for immunization against chikungunya virus infection in individuals 12 years of age and older. Bavarian Nordic will submit additional data over the coming months, aiming to complete the BLA submission before the end...

COPENHAGEN, Denmark, April 22, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. The transactions concern the vesting of restricted stock units (RSUs) awarded to members of the Board of Directors of Bavarian Nordic A/S as part of their remuneration for 2021, and in accordance with the decision by...

COPENHAGEN, Denmark, April 16, 2024 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2023 was adopted. The Board of Directors’ proposal to transfer the Company’s result to 2024 was also adopted. The Remuneration Report for 2023 was approved. The Board of Directors and the Board of Management were discharged from liability. Luc Debryune, Anders Gersel Pedersen, Frank Verwiel, Anne Louise Eberhard, Heidi Hunter and...

COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS ® , the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS ® by establishing additional pathways for vaccine procurement, distribution, and reimbursement by both public and private payers. Since 2022, in response to the global mpox outbreak, JYNNEOS has been made available through public health channels for individuals...